Insights into ASX Stocks
Is Paradigm Biopharmaceuticals (ASX: PAR) Bottoming Out After Its Prolonged Downtrend?
Paradigm Biopharmaceuticals (ASX: PAR) is an Australian late-stage biotech developing injectable PPS, mainly for osteoarthritis. Its shares have fallen more than 95% since 2020 amid trial delays, dilution and losses, with August 2026 Phase 3 interim data now the key catalyst.
Can Bellevue Gold (ASX: BGL) Sustain Its Production Momentum as Grades Rise and Free Cash Flow Surges?
Bellevue Gold (ASX: BGL) is lifting production, lowering costs, and generating record free cash flow as higher grade zones come online and hedge commitments fall, positioning the company for a multi year re rating.
Can Cleanaway (ASX: CWY) Re Rate Higher as Margins Expand and Strategy 2030 Takes Hold?
Cleanaway (ASX: CWY) is rebuilding momentum through upgraded EBIT guidance, margin expansion, and a stronger strategic framework, with valuation support emerging as earnings and free cash flow accelerate.
Is Vault Minerals (ASX: VAU) Building a Base at Key Technical Support After Its 2025 Peak?
Vault Minerals, an ASX-listed mid-tier gold producer, is testing key long-term support after a 2025 peak. Despite strong assets and growth plans, merger uncertainty, weaker guidance, cost pressures, and gold-price sensitivity have weighed on sentiment, while technicals suggest base formation.
Can Zip Co (ASX: ZIP) Maintain Its Breakout Momentum to Clear Near-Term Resistance?
Zip Co is recovering from 2026 lows on record earnings, a buyback, and US growth via Stripe. Technically, it broke a downtrend with support near $2.00. Key risks: credit quality, US concentration, and competition.
Can SRG Global (ASX: SRG) Sustain Its Breakout After Securing $1.85bn of Contracts?
SRG Global (ASX: SRG) surged after securing $1.85 billion of new contracts, upgrading FY26 EBITDA guidance, and initiating FY27 EBITDA guidance of $190m-$200m. Future performance depends on delivering sustained earnings growth across its diversified infrastructure portfolio.